The Polymorphic Metabolism of Dextromethorphan

@article{Woodworth1987ThePM,
  title={The Polymorphic Metabolism of Dextromethorphan},
  author={James R. Woodworth and S R Dennis and Laura E. Moore and Keith S Rotenberg},
  journal={The Journal of Clinical Pharmacology},
  year={1987},
  volume={27}
}
The ability of healthy male volunteers to metabolize a 30‐mg oral dose of dextromethorphan (DM) was studied in 252 Americans. Two blood samples were collected at four and 24 hours after administration of the dose. The resulting plasma was analyzed for unchanged DM. The volunteers were classified as slow, intermediate, or fast metabolizers on the basis of plasma concentrations of DM. Further differentiation of slow and intermediate metabolizers was achieved by comparing the two‐point estimates… 
Bioavailability Evaluation of a Controlled‐Release Dextromethorphan Liquid
TLDR
Comparisons made between the two formulations indicated that the CR DM suspension was bioequivalent to the IR DM solution at steady state, while producing a prolonged release of the drug over time.
Pharmacokinetics of dextromethorphan and dextrorphan in epileptic patients
TLDR
DM given in doses up to 50 mg/6 h can produce plasma and brain concentrations similar to the in vitro antiepileptic levels, without causing significant adverse effects.
Dextromethorphan in nonketotic hyperglycinaemia: metabolic variation confounds the dose-response relationship
TLDR
Levels of DM and its primary metabolite dextrorphan (DX) were utilized to guide DM therapy and exhibited patterns reflective of the extensive and poor metabolizer phenotypes for CYP2D6, the cytochrome P450 isoform responsible for DM metabolism.
Genetic polymorphism in drug oxidation.
  • W. Kalow
  • Chemistry, Medicine
    Psychopharmacology series
  • 1989
TLDR
Of interest and clinical importance is the inhibition of debrisoquine hydroxylase by inhibitors such as quinidine and by some neuroleptics; also the simultaneous use of two substrates has led to serious toxicity by mutual metabolic inhibition.
Dextromethorphan metabolism in Jordanians: Dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation
TLDR
A dissociation between dextromethorphan O-demethylation and debrisoquine (D) 4-hydroxylation has been observed and was detected in 55.3% of individuals.
Dextromethorphan Pretreatment Induces Antipyrine Clearance in the Rat
TLDR
The data suggest that the pharmacokinetic characteristic of extensive first-pass metabolism is not necessarily associated with inhibition of drug metabolism, and indicate that dextromethorphan is capable of inducing hepatic microsomal enzymes.
Oxidative polymorphism of dextromethorphan in a Burundi population
SummaryThe wide availability, metabolism by the same cytochrome P 450 as debrisoquine and, above all, the innocuity of dextromethorphan (DMP) favour the frequent choice of this drug as the test
Determination of dextromethorphan and its metabolite dextrorphan in human urine by capillary gas chromatography without derivatization.
  • Y. Wu, Y. Y. Cheng, S. Zeng, M. Ma
  • Chemistry, Medicine
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • 2003
TLDR
The method has been applied to determine the oxidative phenotypes of cytochrome P450 2D6 in a Chinese population with metabolic ratio of DM in human urine by capillary gas chromatography without derivatization.
Pharmacokinetics of dimemorfan phosphate tablets in healthy Chinese volunteers
TLDR
The pharmacokinetic parameters after single-dosing of 20 mg dimemorfan phosphate tablets under fed conditions were similar with those under fasting conditions, and sex did not affect the pharmacokinetics of dimemor phosphate tablets.
Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity.
TLDR
Analytical and clinical data are described that will help evaluate the use of DM hydrobromide as a probe of CYP3A activity and DM appears to be a promising way to simultaneously phenotype patients for CYP2D6 and CYP 3As.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Polymorphism of carbon oxidation of drugs and clinical implications.
TLDR
The hydroxylation defect shown for debrisoquine metabolism carries over to the oxidative metabolism of phenacetin and guanoxan, and methods for evaluating the metabolism of new drugs in respect of usage and side effects need to be revised.
A method for studying drug metabolism in populations: Racial differences in amobarbital metabolism
TLDR
Measuring the metabolite/creatinine ratios narrowed the distribution range of the data, particularly after correction for sex difference in creatinine, but population differences were not changed.
Inter-individual variation in the metabolism of dextromethorphan
Abstract After ingestion of 25 mg of dextromethorphan-HBr in 12 healthy volunteers, the plasma concentrations of dextromethorphan and conjugated dextrorphan as well as the cumulative excretion of
Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism
TLDR
The ability of normal subjects to hydroxylate mephenytoin or debrisoquine after oral dosing was investigated in 156 unrelated Caucasians living in middle Tennessee, and it is suggested that 4‐hydroxylation of mephenYtoin is a new polymorphism independent of that for debrisquine.
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
TLDR
Patients with a genetic defect in drug oxidation, when treated with metoprolol, are likely to have high plasma concentrations and a prolonged effect, as indicated by the AUC, half-life and duration of beta-adrenoceptor blockade on day 7.
Defective Oxidation of Drugs: Pharmacokinetic and Therapeutic Implications
TLDR
It was observed that 4-hydroxylation of debrisoquine and N-oxidation of sparteine, the metabolic processes removing most of the drug from the body, were grossly impaired or nearly absent in some subjects, and the recent finding that non- and poor metaboliser subjects have an impaired capacity to carry out stereospecific E-10-hydrogenation of nortriptyline might suggest monogenic control of this benzylic hydroxylated reaction.
Polymorphic metabolism of beta-adrenoceptor antagonists.
TLDR
Oxidation phenotype correlates well with intensity and duration of beta-adrenoceptor blockade after metoprolol, PM subjects requiring only once-daily dosing, however, in EM subjects twice- daily dosing is required even if slow release preparations are used, since plasma metoprool concentrations may remain negligible 24 h after dosing.
Polymorphic ability to metabolize propranolol alters 4‐hydroxypropranolol levels but not beta blockade
TLDR
Despite the substantial difference in production of the pharmacologically active 4‐OH metabolite, no difference was seen in the extent of β‐blockade induced in the extensive and poor metabolizers, which implies that 4‐ OH propranolol does not contribute substantially to β‐ blockade.
Pharmacogenetics of Tolbutamide Metabolism in Humans
TLDR
Evidence is provided for monogenic control of tolbutamide metabolism in man and the results suggest that fixed dosage regimens of this drug, as were prescribed in the controversial University Group Diabetes Program study, might lead to higher accrued blood levels in slow inactivators.
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
TLDR
The pharmacokinetics and pharmacodynamics of propranolol (80 mg by mouth) were studied in seven extensive and four poor metabolisers of debrisoquine and no significant difference was detected in the oral clearance of unchanged drug between the two groups of debrisquine oxidation phenotypes.
...
1
2
3
4
...